These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24168097)

  • 1. Clinical applications of attenuated MVA poxvirus strain.
    Gómez CE; Perdiguero B; García-Arriaza J; Esteban M
    Expert Rev Vaccines; 2013 Dec; 12(12):1395-416. PubMed ID: 24168097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
    Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
    J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.
    Boukhebza H; Bellon N; Limacher JM; Inchauspé G
    Hum Vaccin Immunother; 2012 Dec; 8(12):1746-57. PubMed ID: 22894957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
    Volz A; Sutter G
    Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
    Verheust C; Goossens M; Pauwels K; Breyer D
    Vaccine; 2012 Mar; 30(16):2623-32. PubMed ID: 22342706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
    Alharbi NK
    Hum Vaccin Immunother; 2019; 15(1):203-209. PubMed ID: 30148692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
    Esteban M
    Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
    Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
    Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells.
    Nemecková S; Hainz P; Otáhal P; Gabriel P; Sroller V; Kutinová L
    Acta Virol; 2001; 45(4):243-7. PubMed ID: 11885931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
    Bejon P; Mwacharo J; Kai OK; Todryk S; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
    Vaccine; 2006 May; 24(22):4709-15. PubMed ID: 16621181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
    Hanke T; McMichael AJ; Dennis MJ; Sharpe SA; Powell LA; McLoughlin L; Crome SJ
    Vaccine; 2005 Feb; 23(12):1507-14. PubMed ID: 15670887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
    Guerra S; Nájera JL; González JM; López-Fernández LA; Climent N; Gatell JM; Gallart T; Esteban M
    J Virol; 2007 Aug; 81(16):8707-21. PubMed ID: 17537851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization.
    Albrecht M; Suezer Y; Staib C; Sutter G; Vieths S; Reese G
    J Gene Med; 2008 Dec; 10(12):1324-33. PubMed ID: 18816482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.
    Waibler Z; Anzaghe M; Ludwig H; Akira S; Weiss S; Sutter G; Kalinke U
    J Virol; 2007 Nov; 81(22):12102-10. PubMed ID: 17855554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
    Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
    Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.